NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call
NeuroMetrix, Inc. (Nasdaq: NURO) announces plans to release its second quarter financial results on July 23, 2020, before market open. A conference call will follow at 8:00 a.m. ET the same day, discussing the results and business developments. Investors can access the call by dialing 844-787-0799 in the US or 661-378-9630 internationally, using confirmation code 4284442. The earnings press release and financial statements will be available on the company's website.
- Upcoming earnings release may provide insight into business performance.
- Conference call allows for direct communication of financial results to investors.
- None.
WOBURN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Thursday, July 23, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on July 23, 2020 to discuss its financial results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 4284442. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.
A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 4284442. The replay will be available for one week after the conference call.
About NeuroMetrix
NeuroMetrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices that are used throughout the world. The Company has three FDA cleared commercial products. DPNCheck® is a point-of-care test that is used to evaluate peripheral neuropathies. ADVANCE™ is a point-of-care device that provides nerve conduction studies as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies. Quell® 2.0 is a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain and is available over-the-counter. For more information, visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
FAQ
When will NeuroMetrix release its Q2 2020 financial results?
What is the timing of the conference call for NeuroMetrix's Q2 earnings?
How can I access the NeuroMetrix Q2 earnings call?
Where can I find NeuroMetrix's earnings press release?
